Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Inducible T-cell co-stimulator (ICOS) · developed by Xencor
Izuralimab is a humanized, Fc-engineered bispecific antibody that binds both PD-1 and ICOS on T cells, including tumor-infiltrating lymphocytes. It blocks PD-1 engagement by PD-L1 and PD-L2 while stimulating ICOS signaling to enhance T-cell activation. It is being studied in multiple advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05879185 | Phase 2 | Sarcoma | Terminated | XNCR |
| NCT03752398 | Phase 1 | Melanoma (Excluding Uveal Melanoma) | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsCervical CarcinomaColorectal CarcinomaEndometrial CarcinomaGastric or Gastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaMelanoma (Excluding Uveal Melanoma)Nasopharyngeal CarcinomaNon-small Cell Lung CarcinomaPancreatic CarcinomaRenal Cell CarcinomaSmall Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckUrothelial Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →